Inflammation and \(\alpha\)-Synuclein’s Prion-like Behavior in Parkinson’s Disease—Is There a Link?

Carla M. Lema Tomé · Trevor Tyson · Nolwen L. Rey · Stefan Grathwohl · Markus Britschgi · Patrik Brundin

Received: 7 February 2012 / Accepted: 4 April 2012 / Published online: 29 April 2012
© The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract Parkinson’s disease patients exhibit progressive spreading of aggregated \(\alpha\)-synuclein in the nervous system. This slow process follows a specific pattern in an inflamed tissue environment. Recent research suggests that prion-like mechanisms contribute to the propagation of \(\alpha\)-synuclein pathology. Little is known about factors that might affect the prion-like behavior of misfolded \(\alpha\)-synuclein. In this review, we suggest that neuroinflammation plays an important role. We discuss causes of inflammation in the olfactory bulb and gastrointestinal tract and how this may promote the initial misfolding and aggregation of \(\alpha\)-synuclein, which might set in motion events that lead to Parkinson’s disease neuropathology. We propose that neuroinflammation promotes the prion-like behavior of \(\alpha\)-synuclein and that novel anti-inflammatory therapies targeting this mechanism could slow disease progression.

Keywords \(\alpha\)-Synuclein · Neuroinflammation · Prion-like · Parkinson’s disease · Synucleinopathies · Dual-hit hypothesis · Proteinopathy

Introduction

Age-related neurodegenerative disorders, including Parkinson’s disease (PD), are neuropathologically characterized by accumulation of misfolded proteins and the loss of neurons along with sustained neuroinflammation. Clinically, PD patients experience both motor (e.g., bradykinesia, resting tremor, rigidity, and postural instability) and non-motor symptoms (e.g., hyposmia, constipation, sleep disturbances, depression, and dementia). Age is considered the single greatest risk factor for developing PD with 4–5 % of people over 85 years developing the disease [1]. In PD, dopamine-producing neurons in the substantia nigra pars compacta (SNpc) die and there is a concomitant decrease of dopaminergic innervation in the striatum. Furthermore, alpha-synuclein (\(\alpha\)-syn) misfolds and forms intraneuronal aggregates in several brain regions. \(\alpha\)-Syn is a 140-amino acid protein encoded by a single gene located in chromosome 4 [2] and was first described to be present in the nucleus and presynaptic terminals of normal neurons [3]. In PD and the related synucleinopathies multiple system atrophy and dementia with Lewy bodies, misfolded and aggregated \(\alpha\)-syn forms intra-cytoplasmic inclusions. In PD, they are located in neurons and are called Lewy bodies (LB) and Lewy neurites (LN) [4–6]. The idea that \(\alpha\)-syn plays a central role in PD pathogenesis is supported by the link between three missense \(\alpha\)-syn mutations, i.e., Ala53Thr [7], Ala30Pro [8], and Glu46Lys [9] and autosomal dominant early-onset PD. Furthermore, multiplications of the gene cause familial forms of neurodegenerative disease with parkinsonian
features [10] and certain SNPs in the \( \alpha \)-syn promoter are associated with increased risk for PD [11]. Recent studies suggest that prion-like cell-to-cell transfer of possibly misfolded \( \alpha \)-syn contributes to the spreading of neuropathology from one brain region to the next [12–17].

Although there is no consensus on the causes of sporadic PD, neuroinflammation appears to play an important role (reviewed in [18]). Several questions still remain: how, if at all, is neuroinflammation linked to \( \alpha \)-syn misfolding and aggregation? For example, does neuroinflammation trigger \( \alpha \)-syn misfolding or does aggregated \( \alpha \)-syn cause microglia activation and neuroinflammation? Furthermore, does neuroinflammation promote cell-to-cell transfer of \( \alpha \)-syn and seeding and development of new \( \alpha \)-syn aggregates? Alternatively, does the inflammatory process delay the prion-like spread of \( \alpha \)-syn? In this review, we will discuss various aspects that drive pathological alterations of \( \alpha \)-syn with a special focus on how neuroinflammation might affect the different steps.

Involvement of Immune Pathways in the Brain of Patients with Parkinson’s Disease

Inflammation is a specialized reaction of the body to harmful agents or insults to tissue. Inflammatory processes in the nervous system are called "neuroinflammation" and they are characteristic to most neurodegenerative diseases, including PD. Classically, inflammation and neuroinflammation involve innate and adaptive immune responses that are regulated by secreted factors (e.g., cytokines, chemokines, complement proteins, acute phase proteins, reactive oxygen species (ROS), and arachidonate metabolites; reviewed in [19, 20]). Interestingly, genetic alterations in several immune function-related genes (e.g., DJ-1, leucine-rich repeat protein kinase-2 (LRRK2) and HLA-DR) can cause familial PD or increase the risk of developing PD (all studies and meta-analyses collected in www.pdgene.org). This points to a key role for immune pathways in the pathogenetic mechanisms of PD which are possibly triggered by aging, oxidative stress, or abnormal forms of \( \alpha \)-syn (reviewed in [21]).

Microglia and astrocytes are resident immune cells of the brain. The expression of specific markers associated with these cells (typically Iba-1, CD11b, and MHC class II for microglia, GFAP for astrocytes) increases with severity of neuroinflammation. Positon emission tomography imaging studies employing microglia-specific markers point to an early involvement and cerebral propagation of neuroinflammation in PD [22, 23]. Histological analysis of the substantia nigra in PD patients shows activated microglia [24–26], a high density of astrocytes [27], and in some cases also infiltrating T lymphocytes [26, 28]. Furthermore, postmortem PD brains exhibit increased levels of tumor necrosis factor (TNF) [29] and interleukin (IL)-1 and IL-6 [30]. The cerebrospinal fluid (CSF) of PD patients differs from that collected from Alzheimer’s disease (AD) patients, other neurodegenerative disorders or healthy individuals [31]. The CSF levels of transforming growth factor \( \beta \)1 and 2 (TGF\( \beta \)1 and TGF\( \beta \)2) [32] and ratios between amyloid-\( \beta \) (A\( \beta \)) 42 with fractalkine/CX3CL1 [33], as well as levels of complement factors C3 and C4 [34], are all altered in PD. Whether the clinical findings should be taken as evidence that neuroinflammation directly contributes to neurodegeneration in PD is not clear. The secreted factors and activated immune cells are not just potentially neurotoxic, but can also exert neuroprotective effects in neurodegenerative disorders (reviewed in [35, 36]).

In summary, signs of neuroinflammation and genetic links between PD and immune function point to a possible role of immune pathways in PD. Whether inflammation is beneficial or detrimental in this context remains unclear and we think it is pertinent to ask the question what role inflammation could specifically play in propagation of synucleinopathy in PD.

Recent Updates About the Link Between \( \alpha \)-Synuclein Aggregation and the Effect of Inflammation

It has been hypothesized that inflammation triggers, or at least contributes to, the development of \( \alpha \)-syn pathology [12]. Indeed, in cellular assays, misfolded \( \alpha \)-syn species can trigger activation of microglia [37–42], one of the hallmarks of the neuroinflammatory process. Although a specific receptor for \( \alpha \)-syn binding to microglia is still unknown, these cells can take up extracellular \( \alpha \)-syn [43, 44] that in turn triggers the release of soluble immune modulators. The vulnerability of dopaminergic neurons to inflammation has also been linked to \( \alpha \)-syn, as genetic ablation of \( \alpha \)-syn in animal models decreases the sensitivity of these cells to inflammatory challenges [45]. Factors released from activated microglia can further enhance oxidative stress, protein misfolding, and aggregation, creating a positive feedback loop promoting degeneration of dopaminergic cells [46, 47]. Together, it remains unclear whether \( \alpha \)-syn aggregation is a cause or consequence of inflammation.

Approximately 90 % of \( \alpha \)-syn found in LBs is constitutively phosphorylated at serine 87 (S87-P) and serine 129 (S129-P). By contrast, less than 5 % of \( \alpha \)-syn is phosphorylated at serine 129 in healthy human brain [48–50]. Phosphorylation of \( \alpha \)-syn in neuronal cell lines has been linked to detrimental activation of microglia in mixed cell culture systems [51], but whether phosphorylation of \( \alpha \)-syn induces inflammation or vice versa is not fully understood. Furthermore, the precise roles of phosphorylation or other post-translational modifications of \( \alpha \)-syn for neurotoxicity, formation of
aggregates, and activation of microglia are not clear, with different studies reporting conflicting results [52–55].

Nitrated forms of α-syn have previously been suggested to be crucial to the pathogenesis of synucleinopathies [56] and nitrated α-syn can trigger inflammation and microglia activation [57, 58]. One study has shown that nitrated α-syn may be able to recruit peripheral leukocytes in cerebral lymph nodes in a toxin-based (systemic injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, (MPTP)) mouse model of PD. The same study also shows that adoptive transfer of T cells from syngeneic mice immunized with nitrated α-syn worsens dopaminergic neuron loss after MPTP treatment of recipient mice [57]. This indicates that certain adaptive immune mechanisms could play a role in PD pathobiology.

A recent study suggests that α-syn may be modulated by inflammation caused by expression of human wild-type or mutant P301L Tau [59]. Both forms of Tau cause microglial changes and increase IL-6 and TNF-α levels while also increasing the levels of endogenous α-syn and S129-P α-syn.

Inflammation and aggregation of α-syn are dynamically interlinked and this interaction probably plays a key role in the pathogenesis of PD. As discussed in this review, there is increasing evidence that α-syn aggregation may be initiated by a seeding mechanism that could spread throughout neurons in a prion-like fashion possibly involving other amyloidogenic proteins. For example, fragments of α-syn are commonly found in Aβ plaques in the brain of AD patients [60], and certain rare mutations leading to familial forms of AD have been associated with LB pathology as well [61, 62]. Aggregation of α-syn and Aβ can trigger neuroinflammation, e.g., it activates microglia (for reviews see [63, 64]). Oxidative stress produced by neuroinflammation is reported to be a cellular consequence of α-syn aggregation, and excessive levels of free ROS can trigger more inflammation and α-syn aggregation [65–67]. This vicious feed-forward loop of aggregation-induced neuroinflammation that in turn causes more aggregation may be a central mechanism in the pathogenesis of PD and other proteinopathies of the brain.

The NAD-dependent deacetylase, sirtuin 1 (SIRT1), has been recently identified as a possible regulator of α-syn aggregation. Sirtuins are known to have anti-aging effects in nematodes and it is suggested that this family of enzymes may also play an important role in the regulation of inflammation (reviewed in depth by Galli et al. [68]). Recently, it was demonstrated that overexpression of SIRT1 in A53T α-syn transgenic mice increases their lifespan and reduces α-syn aggregation, and conversely, knocking-out SIRT1 has the opposite effect [69]. The underlying mechanism has been suggested to be lack of SIRT1-regulated activation of molecular chaperons, which leads to aggregation of α-syn. Thus, sirtuins affect both α-syn aggregation and inflammation and could provide a molecular link between these two processes in PD.

The development and maintenance of dopaminergic neurons is regulated by the orphan receptor Nurr1 [70]. In addition to its role in neurons, loss of Nurr1 also disinhibits the NF-kB signaling cascade in astrocytes and microglia leading to increased secretion of neurotoxic mediators by these cells thereby promoting the loss of dopaminergic neurons in a mouse model of PD [71]. Rare mutations in Nurr1 have been associated with a late-onset familial form of PD, which presents with reduced expression of Nurr1 in somatic cells including peripheral immune cells [72]. This link between Nurr1, inflammation, and PD phenotype is intriguing, but it remains to be shown whether it is relevant to α-syn aggregation.

**Spread of Synucleinopathy and Progression of Parkinson’s Disease**

The extent of α-syn pathology in the brain is believed to correlate to neurological disease stage [73]. Thus, just as the progression of symptoms tends to follow a predictable pattern, e.g., with certain non-motor symptoms preceding the onset of motor dysfunction, the progression of neuropathological changes are believed to follow a highly replicable pattern. Postulated by Braak and colleagues, this progression is divided into six stages in PD, starting first with the simultaneous appearance of α-syn aggregates in anterior olfactory structures and the vagal nerve. Thereafter, the pathology spreads rostrally, indicated by LNs and to some extent LBs. During stage 2, the pathology manifests itself in the caudal raphe nucleus, in the gigantocellular reticular nucleus, and in the coeruleus–subcoeruleus complex. It is not until stage 3 where it appears in the substantia nigra. At stage 4, lesions are detected in proencephalic regions and finally reach areas of neocortex and prefrontal cortex at the last stages [74]. This progressive pattern of appearance of α-syn aggregates in the brain suggests two possible routes for the spread of synucleinopathy into the brain following long and unmyelinated axonal projections, with a retrograde or anterograde progression [75]: first, the gastrointestinal route from the enteric nervous system (ENS) to the central nervous system (CNS) via dorsal motor neurons of the vagus (DMV) and the intermediolateral nucleus of the spinal cord [76–78]; and second, the olfactory route, from the olfactory bulb to the midbrain via other olfactory areas and the limbic system [79].

Several groups have debated the validity of the notion of progression of synucleinopathy and report a broad range of roughly 50–80 % of cases concurring with Braak’s staging [80–82] or concluding that it can be readily applied to most subjects [83]. In addition, other clinical studies on metabolic, structural, and functional data revealed that
neuronal populations are differentially vulnerable to α-syn pathology and hence dysfunction is not in accordance to the proposed staging system [84]. Despite the controversy about the interpretation of neuropathology linked to clinical symptoms, these [80–82] and other studies [85–87] have led to the proposal of a unified staging system for all Lewy body disorders [88].

Interestingly, an estimated proportion of 90 % of PD patients exhibit olfactory deficits [89–91]. Several studies detected olfactory deficits early in the course of the disease, before the appearance of motor symptoms (for review, see [92]). Olfactory disturbances occur both in familial and sporadic forms of PD [90]. Histological studies in PD have also revealed a high degree of degeneration of olfactory cells, especially in the anterior olfactory nucleus (AON), which has been correlated to disease duration and LB load in the AON and olfactory bulb (OB) [90]. Thus, it has been proposed that PD might be primarily a disorder of olfaction [93] and that the olfactory pathways should be of high interest to study early PD stages.

Other histological studies in pre-symptomatic subjects, who go on to develop PD later in life, or PD patients with colonic bacterial infection, demonstrate pathological changes in the ENS that are associated with premotor symptoms involving the gastrointestinal (GI) tract and aggregation of α-syn in the ENS [94–97]. Indeed, the majority of PD patients display accumulation of pathology-related phosphorylated α-syn in enteric neurons [98]. In line with these findings, the DMV connecting the ENS to the CNS has long been known to be severely affected in PD, potentially influencing GI functions [74]. GI-related non-motor symptoms therefore might represent a prodromal stage of PD.

Together, these data suggest that olfactory and enteric regions might be the starting points of the disease that spreads then to the CNS. Based on this idea, Hawkes et al. proposed a dual-hit hypothesis: a neurotropic pathogen could attack the nervous system from two routes—anterogradely through olfactory tracts and retrogradely through the vagal nerve—and this pathogen could enter the brain through the olfactory and enteric epithelium [79, 99]. Apart from targeting neurons directly, it is quite possible that a pathogen triggers local inflammatory processes, which could initiate synucleinopathy in olfactory and enteric regions leading to a progression of pathology. In the following sections, we describe how inflammation in the olfactory system and in the GI tract might be triggers that start the process of α-syn aggregation.

A Possible Role for Neuroinflammation in the Olfactory Bulb as a Trigger for PD

According to histological studies of PD patients’ brains, α-syn abnormalities observed in anterior olfactory structures at Braak’s stage 1 are restricted to the AON and OB [74, 100]. More recent studies have demonstrated that after this step, the pathology spreads slowly into other olfactory regions like the piriform, periamygdaloid and entorhinal cortices, and the olfactory tubercle, without any progression in non-olfactory cortical areas [79].

Post-mortem studies investigating neuroinflammation in PD patients’ brains have focused on midbrain structures. More extensive studies reported activated microglia also in the hippocampus and the temporal and entorhinal cortices [24]. Despite the involvement of olfactory regions in PD and the importance of neuroinflammation in PD, only one study has focused on the OB and demonstrated microgliosis in the OB of PD patients [101]. Due to its proximity to the olfactory epithelium and connections with the periphery, the olfactory system is very sensitive to exogenous pathogens, which might trigger local inflammation.

Sensibility of the Olfactory Epithelium and Olfactory Bulb to Inflammation

The olfactory epithelium is the first point of contact with the external environment. Mucocillaries of the olfactory epithelium act as a partial barrier against exogenous particles in the air [102, 103], but do not provide complete protection (for review see [104]). In humans, the thickness of the olfactory epithelium declines during aging [105] and thereby it might also become more permeable to particles and pathogens, increasing the risk of brain infections.

The organization of the human and rodent olfactory systems is similar [106] despite olfactory functions being less well developed in humans. In both species, the olfactory epithelium neurons, in contact with the external environment, project their axons into the glomerular layer of the OB, where they contact mitral cells, the relay cells of olfactory information. In rodents, these two types of cells have been shown to constitute a route for pathogen entry into the brain [104].

Further, in rodents, the OB contains a very dense population of microglial cells compared to other structures [107, 108], especially in the glomerular layer. A possible role of microglia in the OB is to phagocytose cellular debris [109] resulting from the high turnover of olfactory receptor neurons in the olfactory epithelium. Moreover, the microglia may also phagocytose OB interneurons [110] which are replaced throughout life in rodents, as well as possibly in humans, by adult neurogenesis [111–113]. Finally, OB microglia might also function as a sensor and barrier to exogenous particles and pathogens and could be involved in modulation and potentiation of neuroinflammation and associated disease [114, 115].

Among exogenous particles that can enter the OB, toxins (for review, see [116]), viruses, and particles (ultra-thin particles <100 nm, nanoparticles and microparticles) [99,
have been widely studied. Studies in animal models have demonstrated that pathogens can be either blocked in the glomerular layer of the OB or spread though the axons of mitral cells to higher olfactory structures, such as the olfactory tubercle, amygdala, and olfactory cortex [114, 115].

Viruses Causing Inflammation in Olfactory Structures

The idea of a viral origin of PD was initially based on the observation that people born during the influenza pandemic 1918–1919 exhibit increased risk of developing parkinsonism, or so called post-encephalitic PD [122]. Viral infections during childhood have also been generally associated with higher likelihood of developing PD [123]. Moreover, diseases like asthma and seasonal and allergic rhinitis might be associated with PD [124], suggesting that chronic rhinitis, i.e., rhinitis-related inflammation, might promote the entry of neurotropic pathogens via the olfactory route [79]. Interestingly, influenza A virus has been detected in the SNpc of PD brains [125], and the interferon-induced protein MxA, which plays a role in defense against influenza virus, is associated with LBs [126].

The infection by neurotropic viruses through the olfactory route has been widely studied in experimental animals. Rodent studies demonstrate that various types of viruses entering via the olfactory epithelium can infect different cell types in the OB, leading to dysfunction in olfactory circuits, and to the activation of glial cells located in the outer layers of the OB [114, 117, 119, 127–131]. Depending on the viral dose [115], an immune reaction involving type I interferons (e.g., IFN-α and IFN-β) can sometimes block the propagation of the virus from the OB to other brain regions [132], but the immune reaction can also induce widespread inflammation. The effects of influenza virus infection on olfactory regions have been well described in rodents [117, 128, 133].

Shortly after infusion of a mouse-adapted human influenza virus in the nasal cavity of mice, the viral antigen is found in the OB (and more precisely in glial cells), but not in other brain regions. Production of cytokines, such as IL-1β and TNF-α, increased considerably at the onset of disease. The neuronal release of TNF-α and IL-1β was also increased in other brain regions, including those directly connected with the OB (piriform cortex, olfactory tubercle, central amygdala) and others, such as the hypothalamus. Hence, local infection in the OB can induce inflammatory signals in distant brain regions and can trigger global neuroinflammation.

As mentioned above, activated microglia can phagocytose pathogens and unwanted cells [134] acquire an antigen-presenting cell phenotype and contribute to the recruitment of T cells [135]. ROS and cytokines produced by microglia disrupt the blood brain barrier (BBB) [136, 137], and the effect of these inflammatory mediators is more pronounced in the olfactory epithelium and OB where the BBB already is more permeable than the BBB of other structures [138–141]. Recently, the effect of TNF-α on BBB permeability was shown to favor CNS infection by the West Nile virus in mice [142]. Thus, neuroinflammation in the OB might increase BBB permeability, facilitating the penetration of exogenous pathogens and triggering microgliosis and leukocyte invasion into the OB, sparking off a vicious circle of inflammation. Possibly, a similar mechanism plays a role in humans, after a neurotropic virus infection entering through the nose.

Recently, Jang and colleagues [143] studied the consequences of H5N1 viral infection in C57Bl/6 mice by intranasal inoculation. The H5N1 avian influenza virus spread from the periphery to the CNS (via cranial nerves) and was found in neurons and astrocytes in the solitary nucleus, locus coeruleus, and in periglomerular and mitral cells of the OB. Twenty-one days post inoculation, the virus was no longer found in the brain, but the immune response persisted at least 2 months. Importantly, this study was the first to demonstrate the effect of viral infection on α-syn aggregation. An increase in cellular and secreted phosphorylated α-syn (pSer129) was observed in the OB, locus coeruleus, hippocampus, and brainstem. Moreover, aggregated α-syn was found in the hippocampus, cortex, and brainstem along with a loss of dopaminergic neurons in SNpc [143]. Taken together, these data point to the possibility that viral infection, maybe through inflammatory processes, can increase α-syn phosphorylation and induce/increase aggregation of α-syn in the brain.

Micro- and Nanoparticles Trigger Oxidative Stress and Inflammation in the OB

Certain metal particles might also be involved in PD, for example, LBs in the brain of PD patients have a high content of aluminum [144], or an enhanced risk to develop PD has been reported for subjects on a diet containing high quantities of iron [145]. Several studies have demonstrated that various types of particles (gold, 13C, manganese oxide, titanium dioxide, ferric oxide) can be inhaled, deposited on olfactory epithelium, tracheobronchial epithelium, and in lung alveoli in humans and mice (for review, see [121, 146]). Some particles then reach the CNS through olfactory epithelium and OB [120, 147–151] and may trigger inflammatory processes in the olfactory circuits. For example, in mice, an intranasal administration of Fe2O3 induces microglial proliferation, activation, and recruitment in the OB. In vitro, exposure to Fe2O3 leads to the release of ROS and NO by a microglia cell line that at the same time increases their proliferation [151]. Thus, chronic exposure to air particles, particularly in a polluted environment, could induce a chronic state of inflammation in olfactory and brain.
structures (for an extensive review on the involvement of viruses, particles, and pesticides in PD, see [152]).

**Inflammation Process in the Olfactory Bulb: Local Consequences**

Peripheral injection of lipopolysaccharide (LPS) is a widely used, but not very well understood, method to induce distant immune reactions in the rodent brain. Mori et al. and Ota et al. focused on olfactory regions and showed in mice a significant loss of cells in the OB and an increase in TNF-α and IkBα expression after peripheral LPS injection [153, 154]. Additionally, LPS administration increased expression of TNF receptors 1 and 2, and caspase 8 gene [154], as well as enhanced Fas expression [153]. Two other studies showed that TNF-α itself has deleterious effects on olfactory cells, causing dysfunction of olfactory neurons [155] and inhibiting regeneration of olfactory mucosa [156]. Moreover, when local inflammation in the OB after nasal instillation of a mycotoxin is coupled to a peripheral LPS injection, the expression of immune-stimulating genes is dramatically increased in the olfactory mucosa and the OB. This suggests that the effects of peripheral LPS could magnify apoptosis and inflammation in the olfactory epithelium and OB [118].

In summary, local inflammatory processes can lead to neuronal death and olfactory neuron dysfunction, which may translate into early olfactory impairments occurring in early PD. Thus, exposure to viruses and micro/nano-particles during our lifetime may initiate chronic inflammation through the olfactory network, induce aggregation of α-syn, and cause damage and dysfunctions that accumulate over time. This may enhance early synucleinopathy in OB and contribute to PD initiation and progression (see Fig. 1).

**Neuroinflammation May Promote Progression of Synucleinopathy from the Gastrointestinal Tract to the CNS**

A growing body of evidence suggests that early on in PD, the peripheral nervous system and organs other than the brain are affected by neuropathological and neuroinflammatory events. Pathomechanisms in the ENS have raised interest in PD research due to distinct non-motor symptoms, such as early impairment of the gastrointestinal tract, which has been associated with PD pathology as late as 10 years before the onset of motor symptoms [157]. Several lines of evidence support the idea that the peripheral nervous system is affected by neuroinflammation early in PD, possibly before symptoms become apparent. These findings have implications for understanding the pathogenesis of PD and for the development of new therapeutic strategies.
as dysphagia, constipation, and gastroesophageal reflux, experienced by PD patients [95, 157–161] and, interestingly, by certain elderly healthy individuals with no history of PD [96, 162–164]. Careful histological studies by Braak and colleagues support the hypothesis that accumulation of α-syn in the ENS could occur 20 years before the onset of degenerative changes in the CNS and associated motor symptoms [76, 94, 158, 164, 165]. The spread from the ENS to the CNS was proposed to occur via the DMV and the intermediolateral nucleus of the spinal cord [76, 166, 167]. Very little is known about the mechanisms that may promote this propagation. For example, a prion-like cell-to-cell progression along nerve bundles of the vagus nerve and spinal cord has been suggested [168, 169], which, similar to prion disorder, could involve immune pathways as well [170] (Fig. 2). This finds some clinical support in a study of patients with early stage diagnosed PD, where α-syn staining in the ENS correlated with compromised intestinal barrier integrity. Possible drivers of the observed pathology may have been bacterial and environmental toxins, resulting in increased oxidative stress most likely produced by macrophages in the luminal wall [97]. Yet in another study, patients with prolonged inflammation due to chronic inflammatory bowel disease did not display colonic synucleinopathy [171]. These findings in human patients indicate that acute local immune effects and certain forms of chronic intragastric inflammation may contribute differently to synucleinopathy in the GI.

In order to model some of the putative mechanisms in vivo and to validate clinical observations, appropriate rodent models reflecting the symptoms found in possible early stage diagnosed PD were studied [172]. Some transgenic mice expressing mutant human α-syn encoded on artificial chromosomes reveal early aggregates of α-syn in the ENS and display motor deficits prior to detectable pathology in the CNS [172, 173]. In rats, intragastric injection of a selective proteasome inhibitor induced α-syn aggregation in DMV [174]. In other studies, chronic intragastric administration of the mitochondrial toxin rotenone to rats was reported to induce a progressive accumulation of endogenous α-syn starting in the ENS and reaching the brain along the vagal and spinal cord nerve connections to the substantia nigra [175]. Neuropathological changes in the toxicity-induced PD rat models were accompanied by local neuroinflammation. It can be assumed that the resulting tissue destruction and rotenone directly triggered a local immune activation and together this may have propagated the pathology from the GI system to the brain.

In support of a direct link between PD and gut immune status, it was found that the gene LRRK2, which is the major genetic cause for familial PD [176–180], is also located in a risk region for Crohn’s disease [181], an autoimmune-mediated chronic inflammatory bowel disease. In the brain, neuronal overexpression of LRRK2 accelerated the development of neuropathology in A53T α-syn transgenic mice, whereas its ablation suppresses neuronal aggregation and cytotoxicity of α-syn [182]. In the peripheral immune system, LRRK2 is upregulated in macrophages under inflammatory conditions which promotes the production of ROS, phagocytosis, and killing of bacteria [183]. The link between genetic risk for PD and GI immune mechanisms for LRRK2 is intriguing and warrants further studies to identify possible associations with progression of α-syn aggregation from the ENS to the brain.

Before doing so, a better understanding of the GI immune system is required. The intestines, and in particular the
subepithelial lamina propria, contain the largest pool of tissue macrophages in humans. Thereby, the intestines share physiological similarities with the immune system of the olfactory epithelium. Macrophages in both locations demonstrate a two-edged sword: on one hand, they maintain tissue homeostasis by active phagocytosis of invading pathogens (e.g., bacteria, viruses) in the absence of excessive activation of other immune pathways [108, 166, 184]; on the other hand, they bear the potential to release an arsenal of detrimental cytokines, chemokines, and ROS [179, 180]. Thus, depending on the circumstances, GI macrophages have the potential to harm the surrounding tissue and may play a role in promoting the accumulation of α-syn in enteric nerves, leading to altered gut motility and constipation and, in later stages, to propagation of the pathology to the brain. If this indeed constitutes an etiological trigger in PD, then it could be relevant for developing earlier treatments and diagnosis of the disease.

Mechanisms of Cell-to-Cell Transfer

Post-mortem studies on PD patients who had received intrastriatal grafts of embryonic dopaminergic neurons over 10 years prior to death showed that some of the grafted neurons exhibit LBs and LNs cells [14, 16, 17, 185]. These findings stimulated the hypothesis that misfolded α-syn transferred directly from host brain cells to the grafted neurons. In support of this hypothesis, experiments performed in vitro [186, 187] and in vivo [13, 15, 188] have demonstrated that α-syn indeed can transfer between cells (Fig. 3) in a prion-like fashion. This is of direct relevance for how α-syn pathology might spread throughout the brain during the natural course of PD [12, 75, 168, 189]. For a comprehensive account of what is known about the underlying cellular and molecular mechanisms of cell-to-cell transfer of α-syn, we refer readers to other recent review articles on the topic [190–192] as it is beyond the scope of the current article. In brief, endocytosis [13, 193, 194] is strongly implicated as a α-syn uptake mechanism, and exosomes have been suggested to play a role when α-syn exits from cells. It has also been speculated that direct cell-to-cell transmission of α-syn occurs via tunneling nanotubes (tubes with a diameter <200 nm and containing F-actin) because a prior study demonstrated transfer of prion-protein via such structures [195]. Currently, the evidence linking α-syn misfolding or aggregation with cell-to-cell transfer is largely circumstantial. More studies are required to determine whether an increase of aggregated α-syn in a model system leads directly to an increase of the transfer rate of the protein. These studies are currently ongoing within our and other laboratories and should provide the evidence required to validate this hypothesis. Furthermore, the effects of neuroinflammation on the aforementioned cellular mechanisms are not known and inflammation might affect the rate of cell-to-cell α-syn transfer in either direction. For example, it is conceivable that some aspects of inflammation mitigates interneuronal α-syn transfer because activated microglia may phagocytose extracellular α-syn [44], thereby reducing the likelihood of neuron-to-neuron transfer of pathological α-syn. This hypothesis, however, remains to be tested. On the other hand, it has become clear that exposure of glial cells to α-syn or uptake of α-syn by astrocytes can turn their phenotype into a potentially more detrimental one for neurons [196, 197].

Conclusions and Proposed Hypothesis

Although α-syn aggregation appears to be central to the development and progression of PD pathology, inflammation also plays an important role in this disease. Immune

![Fig. 3](image_url)

**Fig. 3** α-Syn propagates from mouse brain to a graft of dopaminergic neurons. Confocal planes of a tyrosine hydroxylase-positive mouse neuron (green, a) transplanted in the striatum of a mouse overexpressing human α-syn. The arrowheads indicate the localization inside the grafted mouse cell of several human α-syn (red, b) dots, which have been transferred from the host brain. c An overlay of a and b. Scale bar 5 µm. Figure courtesy of Dr. Elodie Angot
activation in the GI tract or in the olfactory system via chemical or virus exposure might trigger α-syn misfolding, subsequent aggregation, and propagation to the brain. It is also possible that neuroinflammation promotes the prion-like transfer of α-syn by increasing its release, increasing its uptake, or both. However, further studies are needed to support this hypothesis. If correct, it will open up new avenues for early detection and therapeutic intervention. For example, one could speculate that it will be possible to develop therapies which slow down the progression of PD by reducing the underlying inflammation and mitigating its effects on cell-to-cell α-syn transfer. In addition, it is conceivable that it would be possible to adopt a preventive strategy and lower the risk of developing PD by treating the triggers of inflammation in the olfactory or gastrointestinal system.

Acknowledgments This work was supported by a European Research Council Advanced Grant, Swedish Research Council, Human Frontier Science Program, the Parkinson Foundation in Sweden, and ERA-Net NEURON–MIPROTTRAN to Patrik Brundin and a Roche Postdoctoral Fellowship to Stefan Grathwohl. Patrik Brundin is a member of BAGADILICO Linnaeus environment and MultiPark strategic research area at Lund University, both of which are sponsored by the Swedish Research Council.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14
2. Chen X, de Silva HA, Pettenati MJ, Rao PN, St George-Hyslop P, Roses AD, Xia Y, Horsburgh K, Ueda K, Saitoh T (1995) The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and Taq RFLP analysis. Genomics 26:425–427
3. Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8:2804–2815
4. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) alpha-synuclein in Lewy bodies. Nature 388:839–840
5. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95:6469–6473
6. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251:205–208
7. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstien J, Boyer R, Stenroos ES, Chandrasekarappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045–2047
8. Kruger R, Kuhn W, Muller T, Wotitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106–108
9. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164–173
10. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hansson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blanqato J, Hardy J, Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:842
11. Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginhina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, Samii A, Snapinn KW, Tsuang DW, Yearout D, Zhang J, Payami H, Zabetian CP (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67:1350–1356
12. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T (2008) Research in motion: the enigma of Parkinson's disease's pathology spread. Nat Rev Neurosci 9:741–745
13. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P (2011) alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121:715–725
14. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14:504–506
15. Kordower JH, Dodiya HB, Kordower AM, Terpstra B, Paumier K, Madhavan L, Sortwell C, Steece-Collier K, Collier TJ (2011) Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 43:552–557
16. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehrcona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14:501–503
17. Kurowska Z, Englund E, Widner H, Lindvalle O, Lia J-Y, Brundin P (2011) Signs of degeneration in 12–22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. J Park Dis 1:83–92
18. Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208:1–25
19. Lucin KM, Wyss-Coray T (2009) Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64:110–122
20. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Transplantation of embryonic neural progenitors into the adult substantia nigra of Parkinson and Huntington disease patients. Nat Med 14:504–506
21. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8:382–397
22. Gerhard A, Pavesse N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21:404–412
23. Ouchi Y, Yagi S, Yokokura M, Sakamoto M (2009) Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 15(Suppl 3):S200–204
24. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 106:518–526

25. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38: 1285–1291

26. McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 76:550–557

27. Damin P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience: 52(1)–6

28. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (2010) Alpha-synuclein activates microglia by its receptors in Parkinson’s disease. Neurosci Lett 129:526–529

29. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 172:151–154

30. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Pruzuntek H, Riederer P (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202:17–20

31. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ (2008) CSF multi-protein profile distinguishes Alzheimer and Parkinson disease. Am J Clin Pathol 129:526–529

32. Vawter MP, Dillon-Carter O, Tourtellotte WW, Carvey P, Freed WJ (1996) TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson’s disease in ventricular cerebrospinal fluid. Exp Neurol 142:313–322

33. Shi M, Zhang J (2011) CSF alpha-synuclein, tau, and amyloid beta in Parkinson’s disease. Lancet Neurol 10:681, author’s reply 681–683

34. Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DB, Shi M, Zhang J (2011) Complement 3 and factor h in human response to toxic alpha-synuclein and microglial neuroregulatory activities. J Neuroimmunopharmacol 3:59–74

35. Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A, Ciborowski P, Cerny R, Gelman B, Thomas MP, Mosley RL, Glanzer JG, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Zweckstetter M, Lashuel HA (2010) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739–29752

36. Fujiwara H, Hasegawa M, Dohmne N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164

37. Paleologou KE, Oueslati A, Shakked G, Resgiplosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, Chiappe D, Moniattre M, Schneider BL, Aebischer P, Eliezer D, Zweckstetter M, Lashuel HA (2010) Phosphorylation at Ser-87 is enhanced in synucleinopathy lesions, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interacions. J Neurosci 30:3184–3198

38. Klegeris A, Pelech S, Giasson BI, Maguire J, Zhang H, McGeer EG, McGeer PL (2008) Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging 29:739–752

39. Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M, Aebischer P (2009) Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson’s disease. Hum Mol Genet 18:872–887

40. Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T (2011) Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease. J Neurosci 31:16884–16894

41. Lee KW, Chen W, Junn E, Im JY, Grosso H, Sondalla PK, Feng X, Ray N, Fernandez JR, Chao Y, Masliah E, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM (2011) Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J Neurosci 31:6963–6971

42. Oueslati A, Paleologou KE, Schneider BL, Aebischer P, Lashuel HA (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson’s disease. J Neurosci 32:1536–1544
56. Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, Gollomp SM, Ischiropoulos H, Lee VM, Trojanowski JQ (2000) Widespread nitrification of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 157:1349–1445

57. Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, Nemacheck C, Ciborowski P, Przedborski S, Mosley RL, Gendelman HE (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3:e1376

58. Gao H-M, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VMY (2008) Neuroinflammation and oxidation/nitrification of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28:7687–7698

59. Khandelwal PJ, Dumanis SB, Herman AM, Rebeck GW, Moussa CE (2012) Wild type and P301L mutant Tau promote neuroinflammation and alpha-Synuclein accumulation in lentiviral gene delivery models. Mol Cell Neurosci 49:44–53

60. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Ishikawa A, Piao YS, Miyashita A, Kuwano R, Onodera O, Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis RL, Gendelman HE (2008) Nitrated alpha-synuclein overexpression and aggregation exacer-

61. Myohanen TT, Hannula MJ, Van Elzen R, Gerard M, Van Der Gundersen V (2010) Protein aggregation in Parkinson’s disease. Acta Neurol Scand Suppl 190:82-87

62. Gundersen V (2010) Protein aggregation in Parkinson’s disease. Acta Neurol Scand Suppl 190:82–87

63. Doyle KM, Kennedy D, Gorman AM, Gupta S, Healy SJ, Samali A (2011) Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J Cell Mol Med 15:2025–2039

64. Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, Gollomp SM, Ischiropoulos H, Lee VM, Trojanowski JQ (2000) Widespread nitrification of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 157:1349–1445

65. Myohanen TT, Hannula MJ, Van Elzen R, Gerard M, Van Der Gundersen V (2010) Protein aggregation in Parkinson’s disease. Acta Neurol Scand Suppl 190:82-87

66. Ishikawa A, Piao YS, Miyashita A, Kuwano R, Onodera O, Ohtake H, Suzuki M, Nishizawa M, Takahashi H (2005) A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann Neurol 57:429–434

67. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P, Ohtake H, Suzuki M, Nishizawa M, Takahashi H (2005) A mutant PSEN1 causes dementia with Lewy bodies in the third decade of life. Arch Neurol 62:1821–1830

68. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld AM, Nasswetter G, Radrizzani M, Benaroch EE (2011) Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson’s disease patients. Mov Dis: Off J Mov Dis Soc 26:188–190

69. Hawkes CH, Del Tredici K, Braak H (2009) Parkinson’s disease: the dual hit theory revisited. Ann N Y Acad Sci 1170:615–622

70. Kaalaztakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neurophathol Appl Neurobiol 34:284–295

71. Zaccai J, Brayne C, McKee I, Matthews F, Ince PG (2008) Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70:1042–1048

72. Attens J, Jellinger KA (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease. Neuropathol Appl Neurobiol 34:466–467

73. Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407

74. Brooks DJ (2010) Examining Braak's hypothesis by imaging Parkinson's disease. Mov Disord 25(Suppl 1):S83–S88

75. Jellinger KA (2010) Critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 67:550

76. Linazasoro G (2007) Classical Parkinson disease versus Parkinson complex—reflections on stages and in favour of heterogeneous pathology. J Neural Transm 110:517–528

77. Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Ironside JW, Kavantzas N, King A, Korkolopoulou P, Kovacs GG, Meyronet D, Monoranu C, Parchi P, Parkkinen L, Patsouris E, Roggendorf W, Rozemuller A, Stadelmann-Nessler C, Streichenerger N, Thal DR, Kretzschmar H (2009) Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:635–652

78. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Jones Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 157:1349–1445

79. Braak H, Del Tredici K, Braak H (2010) A timeline for Parkinson's disease. Parkinsonism Relat Disord 16:79–84

80. Takahashi H, Suzuki M, Nishizawa M, Takahashi H (1999) [Occurrence of argyrophilic grains in multiple system atrophy: histopathological examination of 26 autopsy cases]. No to shinki = Brain and nerve 51:433–437

81. Cersosimo MG, Perandones C, Micheli FE, Raine GB, Beron AM, Nasswetter G, Radrizzani M, Benaroch EE (2011) Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson’s disease patients. Mov Dis: Off J Mov Dis Soc 26:188–190

82. Hawkes CH, Del Tredici K, Braak H (2009) Parkinson’s disease: the dual hit theory revisited. Ann N Y Acad Sci 1170:615–622

83. Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Ironside JW, Kavantzas N, King A, Korkolopoulou P, Kovacs GG, Meyronet D, Monoranu C, Parchi P, Parkkinen L, Patsouris E, Roggendorf W, Rozemuller A, Stadelmann-Nessler C, Streichenerger N, Thal DR, Kretzschmar H (2009) Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:635–652

84. Brooks DJ (2010) Examining Braak's hypothesis by imaging Parkinson's disease. Mov Disord 25(Suppl 1):S83–S88

85. Jellinger KA (2010) Critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 67:550

86. Linazasoro G (2007) Classical Parkinson disease versus Parkinson complex—reflections on stages and in favour of heterogeneous pathology. J Neural Transm 110:517–528

87. Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Ironside JW, Kavantzas N, King A, Korkolopoulou P, Kovacs GG, Meyronet D, Monoranu C, Parchi P, Parkkinen L, Patsouris E, Roggendorf W, Rozemuller A, Stadelmann-Nessler C, Streichenerger N, Thal DR, Kretzschmar H (2009) Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:635–652

88. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Jones Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 157:1349–1445

89. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197–211

90. Doty RL (2007) Olfaction in Parkinson’s disease. Parkinsonism Relat Disord 13(Suppl 3):S225–S228

91. Morley JF, Duda JE (2010) Olfaction as a biomarker in Parkinson’s disease. Biomark Med 4:661–670

92. Doty RL (ed) (2003) Handbook of olfaction and gustation. Marcel Dekker, New York
intranasal infection of rats with Borna disease virus. J Virol 66:992–998

132. Detje CN, Meyer T, Schmidt H, Kreuz D, Rose JK, Bechmann I, Prinz M, Kalineu U (2009) Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol 182:2297–2304

133. Majde JA, Bohnet SG, Ellis GA, Churchill L, Leyva-Grado V, Wu M, Szentirmai E, Rehman A, Krueger JM (2007) Detection of mouse-adapted human influenza virus in the olfactory bulbs of mice within hours after intranasal infection. J Neurovirol 13:399–409

134. Kim C, Lee SJ (2008) Controlling the mass action of alphasynuclein in Parkinson's disease. J Neurochem 107:303–316

135. Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38:333–347

136. Winkler F, Koedel U, Kastenbauer S, Pfister HW (2001) Differential expression of nitric oxide synthases in bacterial meningitis: role of the inducible isof orm for blood–brain barrier breakdown. J Infect Dis 183:1749–1759

137. Rhodin J, Thomas T, Bryant M, Clark L, Sutton ET (1999) Animal model of vascular inflammation. J Submicrosc Cytol Pathol 31:305–311

138. Dvorska I, Brust P, Hrbas P, Ruhle HJ, Barth T, Ermisch A (1992) On the blood–brain barrier to peptides: effects of immobilization stress on regional blood supply and accumulation of labelled peptides in the rat brain. Endocr Regul 26:77–82

139. Ermisch A (1992) Peptide receptors of the blood–brain barrier and substrate transport into the brain. Prog Brain Res 91:155–161

140. Nonaka N, Farr SA, Kageyama H, Shioda S, Banks WA (2008) Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J Pharmacol Exp Ther 325:513–519

141. Yamada K, Hasegawa M, Kametani S, Ito S (2007) Nose-to-brain delivery of TS-002, prostaglandin D2 analogue. J Drug Target 15:47

142. Fang X, Hou X, Li F (2006) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56:446–451

143. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H (2009) Dietary fats, cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism Relat Disord 15:47–52

144. Ober dorfer G, Ober dorfer E, Ober dorfer J (2005) Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113:823–839

145. Calderon-Garciduenas L, Maronpot RR, Torres-Jardon R, Henriquez-Roldan C, Schoon hoven R, Acuna-Ayala H, Villarreal-Cald erson A, Nakamura J, Fern ando R, Reed W, Azarelli B, Sweeney JB (2003) DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration. Toxicol Pathol 31:524–538

146. Elder A, Gelein R, Silva V, Feikert T, Opan shuk L, Carter J, Potter R, Maynard A, Ito Y, Finkelstein J, Ober dorfer G (2006) Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 114:1172–1178

147. Garcia GI, Kimbell JS (2009) Deposition of inhaled nanoparticles in the rat nasal passages: dose to the olfactory region. Inhal Toxicol 21:1165–1175

148. Yamada K, Hasegawa M, Kametani S, Ito S (2007) Nose-to-brain delivery of TS-002, prostaglandin D2 analogue. J Drug Target 15:47

149. Garcia GI, Kimbell JS (2009) Deposition of inhaled nanoparticles in the rat nasal passages: dose to the olfactory region. Inhal Toxicol 21:1165–1175

150. Tin Win S, Mitsumoto D, Yamamoto S, Fukushima A, Funabashi T, Kobayashi T, Fujimaki H (2008) Changes in neurotransmitter levels and proinflammatory cytokine mRNA expressions in the mice olfactory bulb following nanoparticle exposure. Toxicol Appl Pharmacol 226:192–198

151. Wang Y, Wang B, Zhu MT, Li M, Wang HJ, Wang M, Ouyang H, Chai ZF, Feng WY, Zhao YL (2011) Microglial activation, recruitment and phagocytosis as linked phenomena in ferric oxide nanoparticle exposure. Toxicol Lett 205:26–37

152. Prediger RD, Aguier AS Jr, Matheus FC, Walz R, Antoury L, Raisman-Vozari R, Doty RL (2012) Intranasal administration of neurotoxins in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotox Res 21:90–116

153. Mori K, Kaneko YS, Nakashima A, Nagatsu I, Takahashi H, Ota A (2005) Peripheral lipopolysaccharide induces apoptosis in the murine olfactory bulb. Brain Res 1039:116–129

154. Ota A, Mori K, Kaneko YS, Nakashima A, Nagatsu I, Nagatsu T (2008) Peripheral lipopolysaccharide administration affects the olfactory dopamine system in mice. Ann N Y Acad Sci 1148:127–135

155. Sultan B, May LA, Lane AP (2011) The role of TNF-alpha in inflammatory olfactory loss. Laryngoscope 121:2481–2486

156. Turner JH, LIang KL, May L, Lane AP (2010) Tumor necrosis factor alpha inhibits olfactory regeneration in a transgenic model of chronic rhinosinusitis-associated olfactory loss. Am J Rhinol Allergy 24:336–340

157. Cersosimo MG, Perdonones C, Micheli FE, Raina GB, Beron AM, Nasswetter G, Radrrizzani M, Benaroch EE (2011) Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. Mov Disord 26:188–190

158. Braak H, de Vos RA, Bohl J, Del Tredici K (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396:7–12

159. Edwards LL, Quigley EM, Pfeiffer RF (1992) Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42:726–732

160. Lebouvier T, Chaumette T, Damier P, Coron E, Touchefeu Y, Vignaud S, Naveilhan P, Galniche JP, Bruley des Varannes S, Dckerinderen P, Neunlist M (2008) Pathological lesions in colonic biopsies during Parkinson disease. Gut 57:1741–1743

161. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 119:703–713

162. Bloch A, Probst A, Bissig H, Adams H, Toloray M (2006) Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unpaired elderly subjects. Neuropathol Appl Neurobiol 32:284–295

163. Probst A, Bloch A, Toloray M (2008) New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur J Neurol: The Off J Eur Fed Neurol Soc 15(Suppl 1):1–4

164. Schapira AH, Tola S E (2010) Molecular and clinical prodrme of Parkinson disease: implications for treatment. Nat Rev Neuro 6:309–317

165. Ueki A, Otsuka M (2004) Life style risks of Parkinson's disease: the peripheral autonomic nervous system become central? Eur J Neurol: The Off J Eur Fed Neurol Soc 15(Suppl 1):1–4

166. Wakabayashi K, Toyoshima Y, Awamori K, Anzateki Y, Yoshihito M, Tsuji S, Takahashi H (1999) Resticted occurrence of Lewy bodies in the dorsol vagal nucleus in a patient with late-onset parkinsonism. J Neurol Sci 165:188–191
